- Home
- PRMB vs MRNA Comparison
PRMB vs MRNA Comparison
Compare PRMB & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRMB
- MRNA
- Stock Information
- Founded
- PRMB 1955
- MRNA 2010
- Country
- PRMB United States
- MRNA United States
- Employees
- PRMB N/A
- MRNA N/A
- Industry
- PRMB
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRMB
- MRNA Health Care
- Exchange
- PRMB Nasdaq
- MRNA Nasdaq
- Market Cap
- PRMB 10.7B
- MRNA 10.9B
- IPO Year
- PRMB N/A
- MRNA 2018
- Fundamental
- Price
- PRMB $22.61
- MRNA $24.84
- Analyst Decision
- PRMB Strong Buy
- MRNA Hold
- Analyst Count
- PRMB 11
- MRNA 19
- Target Price
- PRMB $38.64
- MRNA $43.50
- AVG Volume (30 Days)
- PRMB 4.9M
- MRNA 11.7M
- Earning Date
- PRMB 08-07-2025
- MRNA 11-06-2025
- Dividend Yield
- PRMB 1.76%
- MRNA N/A
- EPS Growth
- PRMB N/A
- MRNA N/A
- EPS
- PRMB N/A
- MRNA N/A
- Revenue
- PRMB $6,046,100,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- PRMB $33.90
- MRNA N/A
- Revenue Next Year
- PRMB $3.75
- MRNA $10.17
- P/E Ratio
- PRMB N/A
- MRNA N/A
- Revenue Growth
- PRMB 26.25
- MRNA N/A
- 52 Week Low
- PRMB $22.43
- MRNA $23.15
- 52 Week High
- PRMB $35.85
- MRNA $75.37
- Technical
- Relative Strength Index (RSI)
- PRMB 49.17
- MRNA 45.44
- Support Level
- PRMB N/A
- MRNA $23.18
- Resistance Level
- PRMB $25.32
- MRNA $25.90
- Average True Range (ATR)
- PRMB 0.52
- MRNA 1.14
- MACD
- PRMB -0.94
- MRNA 0.13
- Stochastic Oscillator
- PRMB 88.29
- MRNA 61.03
About PRMB Primo Brands Corporation Class A Common Stock
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.